Celltrion gains Canadian 인터넷 바카라 사이트 for bone disease treatment 'STOBOCLO-OSENVELT'
- Denosumab-based STOBOCLO-OSENVELD wins Canadian 인터넷 바카라 사이트, accelerating entry into North American market - Entry into Canadian market following Korea, Europe, and U.S. accelerates push into KRW 9 trillion global denosumab market - Pro-biosimilar policy accelerates portfolio expansion in Canada, including bone disease treatments
[by Kang, In Hyo] Celltrion announced on September 25 that it has obtained marketing 인터넷 바카라 사이트 from Health Canada for its bone disease treatment, ‘STOBOCLO-OSENVELT,’ a biosimilar to ‘Prolia-Xgeva (denosumab).’
With this 인터넷 바카라 사이트, STOBOCLO-OSENVELT will be launched in Canada with a full label, covering all indications of the original drug, including postmenopausal osteoporosis, prevention of bone metastases in cancer patients, and treatment of giant cell tumor of bone.
Canada represents a substantial denosumab market, estimated at approximately USD 180 million (KRW 252 billion, IQVIA) in 2024. The country is also regarded as one of the most biosimilar-friendly markets, actively encouraging biosimilar prescriptions. As such, Celltrion expects this 인터넷 바카라 사이트 to serve as a strategic bridgehead for bolstering its competitiveness in the broader North American denosumab market, including the United States.
Celltrion is further strengthening its market presence in Canada by securing 인터넷 바카라 사이트s for a range of new products, including bone disease and allergy treatments, in addition to its established portfolio of autoimmune and oncology treatments. The company currently markets or has 인터넷 바카라 사이트s for nine major products in Canada: REMSIMA (marketed as REMDANTRY in Canada), REMSIMA SC, YUFLYMA, and STEQEYMA (autoimmune disease treatments); HERZUMA, TRUXIMA, and VEGZELMA (oncology); OMLYCLO (allergy); and STOBOCLO-OSENVELT (bone disease). Regulatory reviews are also underway for EYDENZELT (ophthalmology) and AVTOZMA (autoimmune disease), with 인터넷 바카라 사이트s anticipated in the future.
Celltrion previously obtained domestic 인터넷 바카라 사이트 for STOBOCLO and OSENVELT in November 2024, followed by European 인터넷 바카라 사이트 in February and U.S. 인터넷 바카라 사이트 in March of this year. With Canadian 인터넷 바카라 사이트 now secured, the company aims to expand its reach in North America, the world's largest pharmaceutical market, and solidify its position in the global denosumab market.
Prolia-Xgeva, the original product for STOBOCLO-OSENVELT, recorded combined global sales of approximately USD 6.599 billion (KRW 9.2 trillion) in 2024. According to IQVIA, the North American market, including the U.S. and Canada, accounted for roughly USD 5.047 billion.
“With the 인터넷 바카라 사이트 of STOBOCLO-OSENVELT, we have expanded our product portfolio in Canada, a market known for its pro-biosimilar policies, while further strengthening our presence in North America, the world’s largest biopharmaceutical market,” a Celltrion official said. “We will concentrate on completing the remaining commercialization procedures, accelerate our entry into the global market, and ensure that other upcoming pipeline products continue to secure 인터넷 바카라 사이트s.”